Improving women's health through modernization of our bioinformatics infrastructure.
Our nationwide bioinformatics infrastructure used to detect important sex differences associated with medical product use is antiquated. The Food and Drug Administration (FDA) has embarked on an ambitious bioinformatics modernization effort that will improve our ability to assess the safety and effectiveness of new medical products. This, in turn, will improve our ability to detect important sex differences.
Oliva
A
A
Office of Critical Path Programs, Food and Drug Administration, Rockville, Maryland, USA. armando.oliva@fda.hhs.gov
Pinnow
E
E
Levin
R
R
Uhl
K
K
D002986:Clinical Trials as Topic; D019295:Computational Biology / Q000458:organization & administration*; D003257:Consumer Product Safety; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D033181:Information Dissemination; D008297:Male; D018579:Patient Selection; D016730:Program Development; D018570:Risk Assessment; D012737:Sex Factors; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration*; D016387:Women's Health